Search
SOLACI Congress
HomeFileStructural heart disease

Structural heart disease

View Category

Other

Tricuspid Regurgitation, TriBicaval Registry

Tricuspid regurgitation (TR) is a condition whose prevalence is expected to increase in the coming years. Surgery...
Dr. Carlos Fava -
Learn More
Mitral valve

Edge-To-Edge Treatment with PASCAL: Are There Sex-Specific Differences?

Mitral regurgitation (MR) is a common valve disease associated with heart failure, hospitalizations, and mortality.  In women, it...
Dr. Carlos Fava -
Learn More
Structural heart disease

ESC 2025 | DOUBLE-CHOICE: Anesthesia Strategies and Self-Expanding Valves in TAVI

TAVI has become the predominant treatment for severe aortic stenosis. The DOUBLE-CHOICE trial analyzed two key aspects:...
Dr. Omar Tupayachi -
Learn More
Pharmacology

Can Colchicine Reduce Post-TAVR Conduction Disturbances?

Courtesy of Dr. Juan Manuel Pérez. Partly caused by perioperative inflammation, conduction disturbances often follow TAVR. Colchicine, known...
Dr. Juan Manuel Pérez -
Learn More
Antithrombotic Anticoagulants

8 Questions About Left Atrial Appendage Closure: Contributions from the 2025 SCAI/HRS Review

Courtesy of Dr. Juan Manuel Pérez. Percutaneous left atrial appendage occlusion (LAAO) is an alternative to oral anticoagulation...
Dr. Juan Manuel Pérez -
Learn More
Left Atrial Apendix Closure

Clinical Impact of Peridevice Leak Following Left Atrial Appendage Closure

Left atrial appendage closure (LAAO) has consolidated as a valid strategy for thromboembolic event prevention in patients...
Dr. Omar Tupayachi -
Learn More
Structural heart disease

TRIPLACE Registry: Conduction Disorders Following Transcatheter Tricuspid Valve Replacement

Tricuspid regurgitation (TR) has become increasingly common and has been associated to hospitalization for cardiac failure and...
Dr. Carlos Fava -
Learn More
Structural heart disease

Conduction Disorders in TAVR: Is Colchicine Useful?

TAVR has shown significant benefit and is increasingly used in severe aortic stenosis, especially in lower risk...
Dr. Carlos Fava -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Tricuspid Regurgitation, TriBicaval Registry

Dr. Carlos Fava - 0
Tricuspid regurgitation (TR) is a condition whose prevalence is expected to increase in the coming years. Surgery presents important challenges and is associated with...

IVI-Guided PCI vs Coronary Artery Bypass Surgery in Left Main Coronary or Multivessel Disease

Dr. Andrés Rodríguez - 0
Several randomized clinical trials have demonstrated the superiority of coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) in patients with left main...

Edge-To-Edge Treatment with PASCAL: Are There Sex-Specific Differences?

Dr. Carlos Fava - 0
Mitral regurgitation (MR) is a common valve disease associated with heart failure, hospitalizations, and mortality.  In women, it is often overlooked and some analyses have...

Institutional News

Watch again – New Guidelines for the Management of Heart Valve Disease: Implications for Interventional Cardiology

solaci - 0
You can now watch our webinar on “New Guidelines for the Management of Heart Valve Disease: Implications for Interventional Cardiology”, held via Zoom on...

ESC 2025: Results of the NEO-MINDSET study — exclusive presentation and analysis with Dr. Pedro Lemos

solaci - 0
Following the presentation of the NEO-MINDSET study in the Late Breaking Clinical Trials sessions at the European Society of Cardiology Congress (ESC 2025), Dr....

SOLACI Webinar – New Guidelines for the Management of Valvular Heart Disease: Implications for Interventional Cardiology

solaci - 0
A new SOLACI virtual scientific event is coming up as part of the scientific coverage of the ESC 2025 Congress. This session will focus on...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy